Jump to content
PathLabTalk

QC Monitoring SD month to month


gilmanch
 Share

Recommended Posts

Hi,

 

I think a good monitoring of your analyzer's performance is looking at your analytes SD from month to month, and it should stay constant. If it changes that could be a sign there is a problem. My question is what is a criteria is used to say there was a change and needs investigation? 10%, 20%, 30% differenence? Or it doubled? What is a good guideline to watch for?

 

Thank you!

Link to comment
Share on other sites

In general I would suppose that a particular analyte's CV% (SD*100/mean) on a particular analyzer should remain constant.  (Note that a SD will vary by QC level, but in general, CV% will only vary by analyte.)

 

So for example, if the CV for a RBC normally runs at 5%, and you start having more than usual random outliers, you might want to check the CV%.  If the QC mean is OK, then no Westgard-style accuracy drift is present.  But if the CV% is running high, the analyzer is probably to blame for an increase in random error.

 

Scott

Link to comment
Share on other sites

[This is intended to be humorous] People from the UK need to add u's or e's to everything, even proper names!

 

OMG the mustached one will be unhappy I have added a U to his name.

 

And pst - we don't add them, they were always there. It's lazy ass Americans dropping the letters ;) Mind you nothing is as bad as the Southern English teeage 'innit' for lazy talk. 

 

ETA - yes there is! 'Bae' grrrrr

Edited by Auntie-D
Link to comment
Share on other sites

When we had the Advia it would produce a report I think once a week or every so many patient samples.. I think it was called Neut X and Neut Y.  I think coulter has something similar Xbar B or something like that.  Our sysmex has it too but its not configured.  It was handy on the Advia as it would give advanced warning of impending doom.  I look at the controls once a week at the L-J chart. Pretty easy to notice trends that way in my opinion although the sysmex has had very few problems with QC (knocking on wood)

Link to comment
Share on other sites

When we had the Advia it would produce a report I think once a week or every so many patient samples.. I think it was called Neut X and Neut Y.  I think coulter has something similar Xbar B or something like that.  

 

It's the moving averages on the advia and does all basic parameters - usually it is set to compare the last 30 results. Any deviation from the mean is flagged - great fun when you put a rack of oncology samples on ;)

 

Ours is set for

 

RBC

MCV

MCH

MCHC

WBC cor - the correction between the perox and baso cell counts

Hb cor -  the correction between the measured and the calculated Hb

MHC cor - the correction between the MCH and CHCM

 

The cut off is a values of below 0.95 or above 1.05 (5%) but people seem to accept anything between 0.8 and 1.2 *sighs*

 

Not sure why there is no platelet moving average though...

 

Neut x/y is the average point of your perox scatter plot - it gives you an idea of the shape of the scatter without having to look at the plot.

Edited by Auntie-D
Link to comment
Share on other sites

Back in the dim times of hematology analysis, there was no such thing as control material for CBC counts.  Even today, lot numbers are only stable for about 6 weeks or so.  So analyzers were equipped with a ridiculously complex statistical analysis package that essentially involves tracking a moving average of parameters.  The idea is that for large batches of patients, certain CBC parameters should not vary much over time. 

 

The XB moving averages monitor RBC, MCV and Hgb only (leaving our distant Lab ancestors to worry over WBC and Plt counts I guess). However, the availability of assayed controls has made dependence on XB as a primary QC method unnecessary.  We still use it for troubleshooting sometime, though.

 

Scott

Link to comment
Share on other sites

Create an account or sign in to comment

You need to be a member in order to leave a comment

Create an account

Sign up for a new account in our community. It's easy!

Register a new account

Sign in

Already have an account? Sign in here.

Sign In Now
 Share

  • Similar Content

    • By Skye
      Hi Everyone,
      I just joined the website and I am hoping that my fellow laboratorians can help me. I recently finished a Joint Commission survey at my facility and I need to write (1) an IQCP for the media that we use in the Microbiology Department as well as (2) an IQCP for the Beckman Coulter MicroScan. I was hoping that someone had a template that would help point me in the right direction. Of course, aspects of the risk assessment (e.g. testing personnel, environment and so forth) will be specific to my facility but it would be great to have something to help point me in the right direction.
      So if anyone could provide me a copy of their template that would be FANTASTIC!!!
       
      I REALLY need an IQCP for the Media and one for the Microscan would be fantastic as well!  
       
      Thanks in advance everyone!!
    • By SMILLER
      We have been having problems for the last month or so with D-dimer QC on our TOPS analyzers.  We are using the regular HemosiL reagents and controls, and no matter what we do, the QC runs with a Mean close to the upper insert range limit on both controls.  Does anyone else have this problem?  
      We have been using these analyzers and IL products for over a year and now this happens. We are wondering if the formulation of the QC has changed.  Once reconstituted, they are supposed to be good for a month in the fridge -- it appears to us that they may be only reliable for about a day. 
      Thanks, Scott
    • By heathervaught
      I need some guidance!  I did a quick search of the forums for any discussion about this, and the most current posting was in 2010.  I'm wondering if anyone has any new information, new experiences, or any advice about CAP TRM.40120.  The note states "...all analysts participate in QC on a regular basis."
      How frequently is "regular"?  For example, when I was looking to complete our annual Competency assessment in September (don't ask...), I was looking for evidence that each individual who performs MTS testing had performed MTS QC.  There were some employees who had not performed MTS QC yet in 2016.  I'm inclined to say that someone who hasn't performed QC in at least 8+ months is not participating in QC on a regular basis.  Being new to my role, I'm just not sure how the assessors interpret this standard, and how others provide evidence of compliance. 
    • By jeloweryii
      Hemo bioscience, an established and growing biotechnology company headquartered in Research Triangle Park (RTP), North Carolina, develops and manufactures immunohematology reagents and related products for the world wide transfusion diagnostics market. Our customers include industry partners, reference laboratories, buying groups, hospital blood banks, and donor centers. Hemo bioscience's in-house research, development and manufacturing activities are led by blood bank trained scientists who are committed to improving the science of transfusion technology.
      When life depends on reliable results, you can rely on Hemo bioscience - "The science in blood banking"
    • By Lingkwyz
      Hi guys,
      I haven't been exposed as a blood banker for quite some time, so please bear with me. Recently, our institution had a case of transfusion reaction (lower back pain) with one unit of PRBCs. The testing details are as follows:
      History: Non-specific reaction (Multiple encounters)
      Pre Transfusion Sample
      Solid Phase : 2 of 3 cels 2+ (Positive
      Gel Card (Regular) : Negative
      Gel Card (Enzyme) : Negative
      Dx: Non-Specific Reaction, all siginificant antibodies excluded
      Transfusion Reaction Investigation Sample
      Solid Phase : 2 of 3 cels 2+ (suggestive with Anti-Jka)
      Gel Card (Regular) : Positive (2+) Minimum grade (Clear-cut Anti-Jka)
      Gel Card (Enzyme) : Positive (4+)  (Clear-cut Anti-Jka)
      DAT (Gel Card) : Positive
      Elution Testing: Anti-Jka Detected
      Dx: Anti-Jka
       
      Analyzing the encounter, me and a colleague, through curiosity re-ran the Pre Transfusion Sample:
      Pre Transfusion Sample: (Curiosity Run)
      Solid Phase : 2 of 3 cels 2+ (suggestive with Anti-Jka)
      Gel Card (Regular) : Positive ; Wp Minimum grade (suggestive with Anti-Jka)
      Gel Card (Enzyme) : Positive ; 1+ Minimum grade (suggestive with Anti-Jka)
       
      Taking all details, I could presume that the Gel Card  results (both regular and enzyme, which I believe was ran at the same time) of the 1st Pre Transfusion Sample was the jinx. So confidence to the testing method lies to the daily QC of the Gel Card which was ran first thing of the day. Now, I'm asking, if Solid-phase technology could incorporate a positive control and negative control to each strip of testing, why aren't there any on the Gel Card Method? Next, if the Solid-phase technology could also incorporate a "system trap" to ensure the addition of patient's sample to the testing, through it's Capture LISS, why cant the Gel Card  do so? I believe that seeing an all-negative resulted panel would be enough for some people for exclusion. Lastly, if reagents aren't available for the Gel card method to ensure the addition of plasma, should our institution enforce a backup procedure that could ensure the reviewer that none of the essential components of the testing (e.g. Patient's plasma) is not missed?
      Hoping for the masters..
       
      Thanks !
       
      lingkywz
       
       
  • Advertisement

×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.